DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Zanubrutinib
Zanubrutinib
Disease(S) Brand Name Drug Name Drug Company Phone Number Website Calaspargase No Financial Assistance Offered at This Asparlas Servier Pegol-Mknl Time
New Drug Updates Brendan Mangan, Pharmd Clinical Pharmacy Specialist Hospital of the University of Pennsylvania
Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
CHMP Agenda of the 19-22 April 2021 Meeting
Treatment of Patients with Relapsed Or Refractory Mantle–Cell
Overview of Planned Or Ongoing Studies of Drugs for the Treatment of COVID-19
In Vitro and in Vivo Studies of Bruton Tyrosine Kinase (Btk) Mutations & Inhibition
(COVID-19) Treatment Guidelines
Multi-Discipline Review
Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020) Liling Huang†, Shiyu Jiang† and Yuankai Shi*
Unitedhealthcare Cancer Therapy Pathways Program Regimens
Application for the Addition of Zanubrutinib on the WHO Model List of Essential Medicines
Drug-Induced Liver Injury (DILI): Current Status and Future Directions for Drug Development and the Post-Market Setting
Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades
Managing Chronic Lymphocytic Leukemia in 2020: an Update on Recent Clinical Advances with a Focus on BTK and BCL-2 Inhibitors
Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
Coronavirus Disease 2019 (COVID-19) Treatment Guidelines
CXCR4 in Waldenström's Macroglobulinema
Top View
Special Issue
Pharmacy Medical Necessity Guidelines: Oral Cancer Medications Effective: August 16, 2021
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance
Using the Structural Kinome to Systematize Kinase Drug Discovery
Coronavirus Disease 2019 (COVID-19) Treatment Guidelines
Therapeutic Advances in Oncology
Simcyptm PBPK Consulting Services Drug Development Decision-Making from Virtual Populations: Proven • Cost-Effective • Efficient
2019 FDA Drug Approvals the FDA Approved 48 New Drugs Last Year, Keeping up the Momentum of Recent Years
A Guide to Cxcr4 Mutations and Their Importance In
Downloaded in Different Formats to Allow an External Analysis of the Data
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Novel Targeted Drugs Approved by the NMPA and FDA in 2019
Pandora's Box: 2019 Oncology and Hematology Drugs
Specialty Pipeline MONTHLY UPDATE
Oral Rx Oncology Order Form
Malignant Hematology
Optimizing the Management of Acute Myeloid Leukemia: Individualized Therapy
2019–2020 Drug Updates in Hematologic Malignancies
Corporate Presentation
Oncology Agents Policy #: Rx.01.67
Polatuzumab Vedotin-Piiq
Fda 131 ° 48 36 # Both* 20 13 8 Ema 126 30 29
Specialty Pipeline MONTHLY UPDATE
June 30, 2021 Total Approvals 269 This Report Will Be Updated January and July of Every Year
Oncology Center of Excellence 2019 Annual Report
How I Manage Chronic Lymphocytic Leukemia
List Item Applications for New Human
WHO Drug Information Contents
Acute Myeloid Leukemia (AML)
Tyrosine Kinase Inhibitors - Oral
Anti-Cancer Drugs Targeting Protein Kinases Approved by FDA in 2020
Update on Oral Oncolytics: a Focus on Hematology Drugs
Updates on the Treatment of Chronic Lymphocytic Leukemia
Generic (Brand) Name Mechanism of Action Mechanism of Action
Malignant Hematology
2021 Interim Results Presentation
Oncology Oral, Hematologic Cancers Therapeutic Class Review (TCR)
Zanubrutinib Fact Sheet
Medicare Part D 2020 Formulary Changes Desert Preferred Choice
The Pharmaceutical Industry in 2019. an Analysis of FDA Drug Approvals from the Perspective of Molecules
Prior Authorization Criteria
October MPU CENTRAL FINAL 2020.Docx
Structure-Based Virtual Screening Reveals Ibrutinib and Zanubrutinib As Potential Repurposed Drugs Against COVID-19